Shots:

• Genevant to receive up to $600M up front and milestone as well as royalties on future product sales
• Takeda get exclusive rights to access Genevant’s LNP technology for a specified number of selected hepatic stellate cells targets
• The companies collaborated to discover- develop and commercialize the LNP-delivered nucleic acid therapeutics directed to previously inaccessible drug targets in hepatic stellate cells to treat liver fibrosis

 ­ Ref: Businesswire | Image: Takeda